Intuitive Surgical reported 16% procedure growth in Q1 2026 and raised its full-year guidance. Robotic surgery is expanding beyond urology into general surgery and gynecology. If you are building a company in this environment, a confirmed market thesis creates a specific and underappreciated execution problem: the pressure to accelerate before you have finished the thing that would actually give you staying power.
If You Are Building a Company in This Environment
When procedure growth numbers beat expectations and a major platform lifts its guidance, the instinct is to treat the news as confirmation that your timing is right and your investment thesis is sound. And often that instinct is correct. The market you identified is growing. The clinical adoption you built your plan around is happening. It is reasonable to feel validated.
The problem is what founders do with that validation. The most common response is to use market momentum as a reason to expand: more indications, more geographies, more product features, more customer segments. The logic is that the window is open and you should move through it as fast as possible before it closes or before competition arrives. This is exactly the kind of decision that looks right from the outside and tends to destroy companies from the inside.
This is the territory Founders Who Finish addresses directly. Not how to capitalize on momentum. How to maintain the execution discipline that produced results in the first place when the environment is actively rewarding you to abandon it.
Why Market Validation Changes Your Execution Problem, Not Your Execution Approach
Robotic surgery procedure growth expanding into general surgery and gynecology means the accounts now converting to robotics have a different clinical champion profile than the early-adopter urology programs. The general surgery champion operates on a different procedural cadence, engages with different evidence requirements, and holds a different position in hospital purchasing. The gynecology champion is often evaluating across a mix of hospital and ASC settings with different procurement timelines.
The mistake founders in adjacent device categories make at this stage is assuming that market validation in one clinical segment transfers automatically to the next. It does not. Evidence that earned you a urology reference site does not move a general surgery committee. A sales process calibrated to the early-adopter account does not work at the new-cohort account that is evaluating its first robotic program. The market is growing, but your specific path inside that market still has to be earned one clinical champion and one reference site at a time.
Founders who finish understand that the goal is not to be present across the full expansion wave. It is to finish something specific and of real value in a defined segment so that you have the credibility and the data to move into adjacent segments on your own terms, not because the market is pulling you there before you are ready.
What the CathWorks Outcome Tells You About the Finish Line
Medtronic closed its $585 million acquisition of CathWorks on April 20, 2026. CathWorks spent years building a reimbursement position for its AI-enabled coronary physiology system, establishing peer-reviewed clinical evidence, and working through the adoption cycle at cath labs. By the time Medtronic closed, CathWorks was not being acquired for its potential. It was being acquired for a finished commercial asset.
That distinction matters. The premium Medtronic paid was for reimbursement, cleared indication, clinical data, and workflow integration at accounts that were already using the system. None of those things exist without finishing. You cannot acquire your way to a reimbursement code. You cannot fabricate two years of real-world outcomes data. The finish line for a strategic acquirer looking at an AI diagnostic tool is not the FDA clearance. It is the complete commercial infrastructure that takes years to build after clearance.
Founders Who Finish is built around the idea that the outcome you are working toward requires finishing specific things at each stage of the company’s development, and that the founders who understand what done looks like at each stage are the ones who tend to be standing when the strategic conversations begin.
What the Execution Framework Looks Like in a Confirmed Market
The five-question framework in Founders Who Finish does not change when the market validates your thesis. What changes is the quality of the answers required.
Question 1
What are you actually finishing?
In an expanding market, the definition of done tends to drift. New indications appear attainable. New segments look adjacent. The accounts that would have been ambitious targets six months ago are now incoming inquiries. Founders who finish resist that drift by keeping the definition of done anchored to the specific clinical evidence and account position they committed to before the momentum arrived.
Question 2
Who decides you are done?
In surgical robotics adjacencies, the stakeholder map shifts as the market expands. The general surgery champion who is now converting to robotics is not the same person as the urology champion who built the original program. Founders who map both clinical and institutional stakeholders for the specific accounts they are targeting tend to close faster than founders who relied on a stakeholder map built around the early-adopter profile.
Question 3
What is the minimum evidence required to get there?
Market growth does not lower the evidence bar. It raises it, because the accounts now evaluating their first robotic program have a larger set of options and more reference points to compare against. The evidence required to earn a new general surgery program is not the same as the evidence that moved a urology early adopter. Founders who scope their evidence plan against the specific decision-maker they need to convince tend to have cleaner data packages and shorter sales cycles.
Question 4
What are you not doing?
In a confirmed market, the cost of saying no to an opportunity is more visible than it was during the period when the market was still uncertain. Founders with discipline say no anyway. The opportunities that feel most urgent in an expanding market are usually the ones that will diffuse your evidence base and delay the reference site that would have moved the next ten accounts. The ability to evaluate an opportunity, see its appeal, and set it aside is harder to maintain when the market is confirming your thesis than when it was not.
Question 5
What does the organization believe about finishing?
Market momentum is the most reliable source of organizational drift. When things are going well, the team starts to believe that the product needs to expand to capture the opportunity, that the current reference site is enough to go broader, that the next hire should be in a new function rather than in the function doing the work that matters most right now. Founders who finish keep the organization focused on a single specific outcome through periods of external validation as well as through periods of uncertainty. The discipline required is the same. The temptation is higher.
The Long-Term Case for Finishing When the Market Is Moving Fast
Intuitive Surgical’s raised guidance and the Q1 procedure growth across general surgery and gynecology represent a genuine expansion of the addressable market for founders building surgical devices and adjacent technology. That expansion will continue. More accounts will convert to robotics in specialties that are currently early in adoption. The installed base of da Vinci 5 systems will grow and so will the clinical champion network that surrounds it.
The companies that build lasting commercial positions in this environment are not the ones that were present across the entire wave as it expanded. They are the ones that finished something specific and of real value in a defined segment, built real accounts with real clinical evidence, and then expanded from that position when they had the credibility to do it deliberately. That is what the CathWorks outcome looks like from the outside. And that is the argument at the center of Founders Who Finish.
Founders Who Finish
The execution guide for founders building in regulated markets
If you are building in surgical robotics, interventional devices, or AI-enabled diagnostic tools, this book is for the decisions you are making in a market that is currently confirming your thesis.
Get the Book